Citations

Clear

9383 citation(s) found for "Thomas, PS".

Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis
White, Thomas A. , Johnson, Tucker F. , Zarzhevsky, Natalia, Tom, Cindy W., Delacroix, Sinny , Holroyd, Eric, Maroney, Susan A. , Singh, Ripudamanjit, Pan, Shuchong, Fay, William P. , Deursen, Jan van, Mast, Alan E. , Sandhu, Gurpreet S. , Simari, Robert D.

Mayo Clinic

Blood | June 2, 2010 | Volume: 116 | Issue: 10 | Pages: 1787-1794

10.1182/blood-2009-10-250910 | PMID 20516367 Get It

AbstractThe antithrombotic surface of endothelium is regulated in a coordinated manner. Tissue factor pathway inhibitor (TFPI) localized at the endothelial cell surface regulates the production of FXa by inhibiting the TF/VIIa complex. Systemic homozygotic deletion of the first Kunitz (K1) domain of TFPI results in intrauterine lethality in mice. Here we define the cellular sources of TFPI and their role in development, hemostasis, and thrombosis using TFPI conditional knockout mice. We used a Cre-lox strategy and generated mice with a floxed exon 4 (TFPIFlox) which encodes for the TFPI-K1 domain. Mice bred into Tie2-Cre and LysM-Cre lines to delete TFPI-K1 in endothelial (TFPITie2) and myelomonocytic (TFPILysM) cells resulted in viable and fertile offspring. Plasma TFPI activity was reduced in the TFPITie2 (71% ± 0.9%, P < .001) and TFPILysM (19% ± 0.6%, P < .001) compared with TFPIFlox littermate controls. Tail and cuticle bleeding were unaffected. However, TFPITie2 mice but not TFPILysM mice had increased ferric chloride–induced arterial thrombosis. Taken together, the data reveal distinct roles for endothelial- and myelomonocytic-derived TFPI.
Surgical Treatment of Extracranial Internal Carotid Artery Dissecting Aneurysms
Piepgras, David G., McCaffrey, Thomas V., Mokri, Bahram, Schievink, Wouter I.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 35 | Issue: 5 | Pages: 809-816

10.1227/00006123-199411000-00002 | PMID 7838327 Get It

Spontaneous Cerebrospinal Fluid Rhinorrhea: Evolving Concepts in Diagnosis and Surgical Management Based on the Mayo Clinic Experience from 1970 through 1981
Hubbard, Jerry L., McDonald, Thomas J. , Pearson, Bruce W. , Laws, Edward R.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 16 | Issue: 3 | Pages: 314-321

10.1227/00006123-198503000-00006 | PMID 3982609 Get It

Abstract Spontaneous cerebrospinal fluid (CSF) rhinorrhea, occurring in the absence of recent trauma, is a distinct clinical entity that can be difficult to diagnose and treat. The case records of 28 patients with this entity were reviewed retrospectively. Pertinent historical data and the results of radiographic evaluation are discussed. The patients were classified into one of three major etiological categories: congenital anomaly, delayed posttraumatic, and tumor groups. The fistulas causing the rhinorrhea were approached extracranially or intracranially, depending on the suspected cause and location. A cure was obtained in 22 of the 27 patients surgically treated (81%). Seventeen patients were cured by a single operation, 5 were cured after multiple operations, and 5 continued to leak despite surgical treatment. Three of the 5 patients who were surgical failures had intracranial tumors, and 2 of them died from complications of persistent fistulas. With the use of a multidisciplinary team approach, an extracranial operation (transethmoidal or transsphenoidal) to repair a spontaneous CSF leak offers a high success rate and is associated with minimal morbidity in appropriately selected patients.
Intraventricular Tension Pneumocephalus as a Complication of Paranasal Sinus Surgery
Davis, D.H., Laws, Edward R. , McDonald, Thomas J. , Salassa, John R., Phillips, Lawrence H.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 8 | Issue: 5 | Pages: 574-576

10.1227/00006123-198105000-00011 | PMID 7266798 Get It

Abstract A case of intraventricular tension pneumocephalus occurring as a complication of paranasal sinus surgery is presented. The pathophysiology of tension pneumocephalus is discussed and emphasis is placed on the potentially life-threatening increase in intracranial pressure that occurs. Tension pneumocephalus requires prompt diagnosis and treatment.
Successful Management of Bilateral Carotid-Cavernous Fistulae with a Trans-sphenoidal Approach
Laws, Edward R. , Onofrio, Burton M., Pearson, Bruce W. , McDonald, Thomas J. , Dirrenberger, Richard A.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 4 | Issue: 2 | Pages: 162-167

10.1227/00006123-197902000-00010 | PMID 440549 Get It

Abstract A patient with traumatic bilateral carotid-cavernous fistulae was successfully treated by an entirely extracranial approach. The larger fistula on the left was exposed via a transethmoidal, trans-sphenoidal route and was directly opened and packed while the cavernous carotid artery was stented open by an intraluminal balloon catheter. The balloon catheter provided temporary hemostasis and was removed after the fistula had been packed. The left carotid artery remained patent, and the smaller fistula on the right was subsequently obliterated by a balloon catheter. The fistulae have remained cured, and the left internal carotid artery supplies the cerebral circulation.
Percutaneous Cryoablation of Masses in a Solitary Kidney
Weisbrod, Adam J. , Atwell, Thomas D. , Frank, Igor, Callstrom, Matthew R. , Farrell, Michael A., Mandrekar, Jayawant N. , Charboneau, J. William

Mayo Clinic

American Journal of Roentgenology | May 20, 2010 | Volume: 194 | Issue: 6 | Pages: 1620-1625

10.2214/ajr.09.2978 | PMID 20489104 Get It

Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study
Silberstein, Stephen D., Cady, Roger , Freitag, Fred, Mathew, Ninan T., Biondi, David M., Ascher, Steven, Olson, William H., Hulihan, Joseph, Lipton, Richard B. , Dodick, David W.

Mayo Clinic

Cephalalgia | May 17, 2010 | Volume: 31 | Issue: 1 | Pages: 18-30

10.1177/0333102410372427 | PMID 20974598 Get It

Objective: The study sought to evaluate whether topiramate prevents development of chronic daily headache (CDH, ≥15 headache days per month) in adult subjects with high-frequency episodic migraine (HFEM, 9–14 migraine headache days/month). A secondary objective was to assess the efficacy of topiramate as preventive migraine treatment in this population. Methods: This was a multicenter, randomized, double-blind, placebo-controlled study comparing topiramate 100 mg/day and placebo for 26 weeks. The primary efficacy variable was new-onset CDH at month 6. Secondary efficacy measures included migraine and headache days. Adverse events (AEs) were evaluated. Results: A total of 159 topiramate subjects and 171 placebo subjects were efficacy-evaluable. At month 6, 1.4% of topiramate subjects versus 2.3% of placebo subjects had CDH ( p = .589). Compared with placebo, topiramate treatment was associated with statistically significant reductions in mean number of migraine days (6.6 vs. 5.3/28 days; p = .001) and headache days (6.6 vs 5.3/28 days; p = .001). Most commonly reported AEs in the topiramate versus placebo group included paresthesia (32.4% vs. 7.0%), fatigue (14.8% vs. 8.6%), dizziness (11.4% vs. 7.6%) and nausea (10.8% vs. 9.2%). Conclusion: Topiramate 100 mg/day did not prevent the development of CDH at six months in subjects with HFEM. Topiramate was effective in reducing headache days and migraine headache days and generally well tolerated.
Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans
Aisen, Paul , Petersen, Ronald C. , Donohue, Michael , Gamst, Anthony, Raman, Rema , Thomas, Ronald G. , Walter, Sarah , Trojanowski, John Q. , Shaw, Leslie M. , Beckett, Laurel , Jack, Clifford R. , Jagust, William J. , Toga, Arthur W. , Saykin, Andrew J. , Morris, John C. , Weiner, Michael W. , Initiative, Alzheimer's Disease Neuroimaging, Green, Robert C. , Initiative, Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Toga, Arthur W , Morris, John C , Donohue, Michael C

Mayo Clinic

Alzheimer's & Dementia | May 7, 2010 | Volume: 6 | Issue: 3 | Pages: 239-246

10.1016/j.jalz.2010.03.006 | PMID 20451872 Get It

The Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has provided clinical, operational, and data management support to ADNI since its inception. This article reviews the activities and accomplishments of the core in support of ADNI aims. These include the enrollment and follow‐up of more than 800 subjects in the three original cohorts: healthy controls, amnestic mild cognitive impairment (now referred to as late MCI, or LMCI), and mild Alzheimer's disease (AD) in the first phase of ADNI (ADNI 1), with baseline longitudinal, clinical, and cognitive assessments. These data, when combined with genetic, neuroimaging, and cerebrospinal fluid measures, have provided important insights into the neurobiology of the AD spectrum. Furthermore, these data have facilitated the development of novel clinical trial designs. ADNI has recently been extended with funding from an NIH Grand Opportunities (GO) award, and the new ADNI GO phase has been launched; this includes the enrollment of a new cohort, called early MCI, with milder episodic memory impairment than the LMCI group. An application for a further 5 years of ADNI funding (ADNI 2) was recently submitted. This funding would support ongoing follow‐up of the original ADNI 1 and ADNI GO cohorts, as well as additional recruitment into all categories. The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations.
Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
Sideras, Kostandinos , Ames, Matthew M. , Loprinzi, Charles L. , Mrazek, David P., Black, John L. , Weinshilboum, Richard M. , Hawse, John R. , Spelsberg, Thomas C., Ingle, James N. , Weinshilboum, Richard M. , Goetz, Matthew P. , Sideras, Kostandinos

Mayo Clinic

Journal of Clinical Oncology | May 3, 2010 | Volume: 28 | Issue: 16 | Pages: 2768-2776

10.1200/jco.2009.23.8931 | PMID 20439629 Get It

Evidence has emerged that the clinical benefit of tamoxifen is related to the functional status of the hepatic metabolizing enzyme cytochrome P450 2D6 (CYP2D6). CYP2D6 is the key enzyme responsible for the generation of the potent tamoxifen metabolite, endoxifen. Multiple studies have examined the relationship of CYP2D6 status to breast cancer outcomes in tamoxifen-treated women; the majority of studies demonstrated that women with impaired CYP2D6 metabolism have lower endoxifen concentrations and a greater risk of breast cancer recurrence. As a result, practitioners must be aware that some of the most commonly prescribed medications coadministered with tamoxifen interfere with CYP2D6 function, thereby reducing endoxifen concentrations and potentially increasing the risk of breast cancer recurrence. After reviewing the published data regarding tamoxifen metabolism and the evidence relating CYP2D6 status to breast cancer outcomes in tamoxifen-treated patients, we are providing a guide for the use of medications that inhibit CYP2D6 in patients administered tamoxifen.